Cannabis Science Inc. Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development
Published: Jun 05, 2012
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (CBIS.OB) announced today the initiation of a research program to explore the commercial development of Phytocannabinoid-based therapeutics for drug resistant HIV infection. The program will facilitate an antiviral investigation of Phytocannabinoids inhibition of HIV TAT. Cannabis Science is a publicly traded, pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges.